British pharmaceutical giant AstraZeneca has reported a significant 38% increase in pre-tax profits to £8.7 billion for 2024, driven by robust sales across its cancer, lung, and immunology treatments portfolio.
British pharmaceutical giant AstraZeneca has reported a significant 38% increase in pre-tax profits to £8.7 billion for 2024, driven by robust sales across its cancer, lung, and immunology treatments portfolio.
Danish pharmaceutical giant Novo Nordisk has projected reduced growth for 2025 amidst mounting competition in the weight-loss drugs market from American rivals. The company, renowned for its obesity treatments Ozempic
Danish pharmaceutical giant Novo Nordisk has reported exceptional third-quarter results, driven by remarkable sales of its weight-loss treatment Wegovy. The anti-obesity medication generated sales of 17.3 billion Danish krone (£1.96
AstraZeneca, one of the world's leading pharmaceutical companies, experienced a significant setback on Tuesday as its stock price plummeted, wiping out £15 billion in market value. This dramatic drop was triggered by a combination of disappointing early data on its weight loss drug candidate and reports of a major fraud case involving company executives in China. Let's delve into the details of these developments and their potential implications for AstraZeneca's future.
Shield Therapeutics, a pharmaceutical company focusing on iron deficiency treatments, has reported a significant increase in revenues for the year 2023. The company’s sales of its Accrufer/Feraccru iron deficiency treatment






